Sentiment Trading

Soleno Therapeutics Inc. has reported a significant increase in revenue and a positive financial performance in Q2, driven by the successful launch of its flagship product VYKAT XR.

Soleno Therapeutics has successfully priced a $200 million public offering to support the launch of its key product VYKAT XR, a rare disease treatment.